Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases

Chronic hemodialysis patients are at high risk of morbidity and mortality in case of SARS-CoV-2 infection and they may need to be treated with monoclonal antibodies, either because they have not been vaccinated, or because they have a low anti spike antibody titer. Administration of Sotrovimab has r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mambelli, Emanuele, Gasperoni, Lorenzo, Maldini, Laura, Biagetti, Carlo, Rigotti, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469048/
https://www.ncbi.nlm.nih.gov/pubmed/36098880
http://dx.doi.org/10.1007/s40620-022-01449-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469048/
https://www.ncbi.nlm.nih.gov/pubmed/36098880
http://dx.doi.org/10.1007/s40620-022-01449-z

Ejemplares similares